Results for unaudited financial results for Quarter and Half year ended September 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indrayani Biotech reported standalone revenue of Rs 3,775 lakhs for Q2 FY26, up about 25% from Rs 3,016 lakhs in Q2 FY25, and Rs 6,791 lakhs for H1 FY26 versus Rs 6,269 lakhs in H1 FY25. The company swung to a profit before tax of Rs 106 lakhs in Q2 FY26 from a small loss in Q2 FY25, and H1 FY26 PBT jumped to Rs 227 lakhs from just Rs 2 lakhs a year ago. Statutory auditor Venkatesh & Co issued an unmodified limited review opinion on both standalone and consolidated results. On the balance sheet, total borrowings of Rs 6,644 lakhs now exceed standalone equity of Rs 5,613 lakhs, pushing the debt-to-equity ratio above 1x. Cash flow from operations was sharply negative at around Rs -1,012 lakhs on a standalone basis for H1. Separately, non-executive director Ms. Lakshmiprabha Kasiraman resigned citing personal reasons, two board committees were reconstituted, and the company disclosed it had paid a BSE fine of Rs 16,520 (including GST) for a delayed appointment of the Compliance Officer under Regulation 6(1).
Strong revenue rebound and a swing back to profitability are positives for shareholders, but the negative operating cash flow and rising debt-to-equity ratio above 1x raise concerns about working capital and leverage. The board-level resignations and past compliance lapses are minor governance flags but have been resolved with fines already paid.